Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer-Reference-Cited by-全球学者库

Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer

Published:2017-02-19 Issue:2 Volume:120 Page:226-232
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Fan Liancheng¹,Wang Yanqing¹,Chi Chenfei¹,Pan Jiahua¹,Xun Shangguan¹,Xin Zhixiang¹,Hu Jianian¹,Zhou Lixin¹,Dong Baijun¹,Xue Wei¹

Affiliation:

1. Department of Urology; Renji Hospital; School of Medicine; Shanghai Jiao Tong University; Shanghai China

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Joint Research Foundation for Innovative Medical Technology of Shanghai Shenkang Hospital Development Center

Shanghai Municipal Education Commission

Shanghai Municipal Commission of Health and Family Planning

Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support

Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai

Innovation Fund for Translational Research of Shanghai Jiao Tong University School of Medicine

Incubating Program for clinical Research

Innovation of Renji Hospital Shanghai Jiao Tong University School of Medicine

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13781/fullpdf

Reference31 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Hormonal therapy in the management of prostate cancer: from Huggins to the present;Garnick;Urology,1997

3. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis;Yuan;Oncogene,2014

4. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

5. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer;Attard;J Clin Oncol,2009

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer;Journal of Clinical Medicine;2023-05-09

2. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration‐resistant prostate cancer;The Prostate;2023-03-16

3. Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer;Journal of Cancer Research and Clinical Oncology;2023-03-13

4. Chromogranin A: a useful biomarker in castration-resistant prostate cancer;World Journal of Urology;2022-12-17

5. Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2021-10